Rehmann Capital Advisory Group grew its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 7.0% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,067 shares of the company’s stock after buying an additional 725 shares during the period. Rehmann Capital Advisory Group’s holdings in Eli Lilly And Co were worth $1,188,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of Eli Lilly And Co in the 2nd quarter worth $114,000. Fort L.P. bought a new position in shares of Eli Lilly And Co in the 2nd quarter worth $121,000. Welch Group LLC bought a new position in shares of Eli Lilly And Co in the 3rd quarter worth $123,000. Zions Bancorporation bought a new position in shares of Eli Lilly And Co in the 3rd quarter worth $128,000. Finally, Mainstay Capital Management LLC ADV lifted its holdings in shares of Eli Lilly And Co by 98.0% in the 3rd quarter. Mainstay Capital Management LLC ADV now owns 1,218 shares of the company’s stock worth $131,000 after purchasing an additional 603 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.
In other news, SVP Alfonso G. Zulueta sold 6,000 shares of the firm’s stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $106.31, for a total transaction of $637,860.00. Following the completion of the sale, the senior vice president now directly owns 55,224 shares of the company’s stock, valued at approximately $5,870,863.44. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Eli & Co Lilly sold 4,500 shares of the firm’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $14.44, for a total value of $64,980.00. Following the sale, the insider now directly owns 3,915,654 shares of the company’s stock, valued at $56,542,043.76. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,962,800 shares of company stock valued at $149,601,553. Insiders own 0.11% of the company’s stock.
A number of brokerages recently issued reports on LLY. TheStreet cut Eli Lilly And Co from a “b” rating to a “c+” rating in a report on Friday, August 24th. Cantor Fitzgerald set a $110.00 target price on Eli Lilly And Co and gave the stock a “buy” rating in a report on Monday, September 17th. Zacks Investment Research upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $129.00 target price on the stock in a report on Tuesday, October 9th. BMO Capital Markets increased their target price on Eli Lilly And Co from $90.00 to $107.00 and gave the stock a “market perform” rating in a report on Wednesday, October 3rd. Finally, JPMorgan Chase & Co. set a $117.00 target price on Eli Lilly And Co and gave the stock an “overweight” rating in a report on Wednesday, September 26th. Nine investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $111.53.
Shares of NYSE:LLY opened at $113.58 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.53 and a debt-to-equity ratio of 0.83. Eli Lilly And Co has a 1-year low of $73.69 and a 1-year high of $119.84. The firm has a market cap of $122.71 billion, a price-to-earnings ratio of 26.54, a P/E/G ratio of 1.81 and a beta of 0.31.
Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings data on Tuesday, November 6th. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.35 by $0.04. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. The business had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same period last year, the business earned $1.05 EPS. The business’s revenue was up 7.1% on a year-over-year basis. As a group, sell-side analysts forecast that Eli Lilly And Co will post 5.58 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be given a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a dividend yield of 1.98%. The ex-dividend date of this dividend is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio is presently 52.57%.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: Dividend Aristocrat Index
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.